Short Interest in Seres Therapeutics, Inc. (NASDAQ:MCRB) Grows By 30.9%

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 799,000 shares, an increase of 30.9% from the April 30th total of 610,400 shares. Based on an average trading volume of 85,200 shares, the short-interest ratio is presently 9.4 days. Approximately 12.4% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

MCRB has been the topic of several recent analyst reports. The Goldman Sachs Group cut their target price on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a research note on Friday, March 14th. Wall Street Zen upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. Finally, Chardan Capital reaffirmed a "neutral" rating and issued a $6.00 target price (up previously from $1.25) on shares of Seres Therapeutics in a research report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $73.67.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vontobel Holding Ltd. lifted its holdings in Seres Therapeutics by 137.6% during the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company's stock valued at $780,000 after purchasing an additional 543,469 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Seres Therapeutics by 15.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock worth $720,000 after buying an additional 117,107 shares during the last quarter. Avantax Advisory Services Inc. grew its stake in Seres Therapeutics by 170.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after buying an additional 28,500 shares during the last quarter. Invesco Ltd. raised its holdings in Seres Therapeutics by 193.2% in the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock valued at $96,000 after acquiring an additional 89,995 shares during the period. Finally, Goldman Sachs Group Inc. lifted its position in Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 21,679 shares during the last quarter. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Trading Up 13.4%

Shares of Seres Therapeutics stock traded up $0.97 during midday trading on Friday, reaching $8.23. The company had a trading volume of 120,268 shares, compared to its average volume of 143,096. The company has a market capitalization of $71.86 million, a price-to-earnings ratio of -35.78 and a beta of 2.89. The stock has a fifty day simple moving average of $8.98 and a 200 day simple moving average of $13.76. Seres Therapeutics has a 1-year low of $6.53 and a 1-year high of $30.60.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). Sell-side analysts expect that Seres Therapeutics will post -0.38 earnings per share for the current year.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.